RBC Capital Defends XenoPort (XNPT); Analyst Notes M&A Potential
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/18/2026
- Wall St ends lower for the day and week as chip selloff broadens
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Why the Fed may still need to hike rates
- Assassin's Creed Black Flag Resynced sells 3M copies in a week
- Magnitude 7.4 earthquake strikes coast of Chiapas, Mexico; Tsunami waves are possible
- Magnitude 7.4 earthquake strikes Puerto Madero, Mexico, USGS says
- Adobe has received a takeover approach by a Big Tech company - Betaville
- Medifast launches Trilivy, replacing its Optavia brand
Further Development of XenoPort (XNPT) '829 is Unwarranted, Cowen Says
September 15, 2015 11:10 AM EDTCowen analyst Eric Schmidt reiterated an Market Perform rating on XenoPort (NASDAQ: XNPT) noting the XP23829 was active in the latest data but "unimpressive."
Schmidt commented, "XenoPort released Phase II data on '829 (a prodrug of monomethyl fumarate) for the treatment of moderate... More
XenoPort's (XNPT) XP-829 Efficacy 'Looks Good' - RBC Capital
September 15, 2015 8:03 AM EDTRBC Capital maintained an Outperform rating on XenoPort (NASDAQ: XNPT) with a price target of $10. Earlier XenoPort announced positive preliminary top-line results from its Phase 2 clinical trial of XP23829 as a potential treatment for moderate-to-severe chronic plaque-type psoriasis. Analyst Michael J. Yee... More
XenoPort (XNPT) Announces Significant Prelim. Top-Line Data from XP23829 Phase 2 in Psoriasis
September 15, 2015 6:34 AM EDTXenoPort (NASDAQ: XNPT) announced positive preliminary top-line results from its Phase 2 clinical trial of XP23829 as a potential treatment for moderate-to-severe chronic plaque-type psoriasis. XP23829 met its primary endpoint in both 800 mg once daily and 400 mg twice daily doses, demonstrating statistically significant improvements in percent change from baseline to week 12 in Psoriasis Area and Severity Index (PASI) score. XP23829 is a patented prodrug of monomethyl fumarate (MMF) in a novel oral formulation that was designed to potentially offer physicians and patients an effective, better tolerated and easier to use therapeutic option to currently... More
